These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1586 related items for PubMed ID: 31816162

  • 1. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK, Ye C, Campbell S, Retnakaran R.
    JACC Heart Fail; 2018 Oct 06; 6(10):823-830. PubMed ID: 30196071
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

  • 9. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.
    Eur J Heart Fail; 2018 May 28; 20(5):853-872. PubMed ID: 29520964
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 May 28; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X, Xu S, Li J, Tong N.
    Front Endocrinol (Lausanne); 2020 May 28; 11():599355. PubMed ID: 33335511
    [Abstract] [Full Text] [Related]

  • 13. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 28; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
    Brønden A, Christensen MB, Glintborg D, Snorgaard O, Kofoed-Enevoldsen A, Madsen GK, Toft K, Kristensen JK, Højlund K, Hansen TK, Søndergaard E, Hansen KB.
    Diabet Med; 2023 Aug 28; 40(8):e15157. PubMed ID: 37249579
    [Abstract] [Full Text] [Related]

  • 16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, de Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC.
    Eur J Heart Fail; 2020 Sep 07; 22(9):1495-1503. PubMed ID: 32618086
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D, Meier JJ, Esposito K.
    Diabetes Obes Metab; 2019 May 07; 21(5):1081-1087. PubMed ID: 30609236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.